First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer:A United States-based cost-effectiveness analysis

Journal of Clinical Oncology

Volumn 33, Issue 10, 2015, Pages 1112-1118

  Goldstein, Daniel A ^a   Chen, Qiushi ^b   Ayer, Turgay ^b   Howard, David H ^a   Lipscomb, Joseph ^a   El Rayes, Bassel F ^a   Flowers, Christopher R ^a  

^a EMORY UNIVERSITY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADD ON THERAPY; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; MARKOV CHAIN; METASTASIS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FLUOROURACIL; HUMANS; LEUCOVORIN; MARKOV CHAINS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84927615521     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.4904     Document Type: Conference Paper

References (41)

1. Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104-117, 2014
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
4. Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008
5. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study. J Clin Oncol 26:3523-3529, 2008
6. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
8. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
9. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
10. Lawrence D, Maschio M, Leahy KJ, et al: Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). J Med Econ 16:1387-1398, 2013
11. Shiroiwa T, Fukuda T, Tsutani K: Costeffectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 29: 2256-2267, 2007
12. Tappenden P, Jones R, Paisley S, et al: The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 43:2487-2494, 2007
13. Auget J-L, Balakrishnan N, Mesbah M, et al: (eds): Advances in Statistical Methods for the Health Sciences: Applications to Cancer and AIDS Studies, Genome Sequence Analysis, and Survival Analysis. Boston, MA, Birkhäuser, 2007
14. Arias E: National vital statistics reports: United States life tables, 2007. http://www.cdc.gov/nchs/ data/nvsr/nvsr59/nvsr59-09.pdf
15. National Cancer Institute: SEER research data 2000-2010. http://seer.cancer.gov/data
16. Ramsey SD, Andersen MR, Etzioni R, et al: Quality of life in survivors of colorectal carcinoma. Cancer 88:1294-1303, 2000
17. Ramsey SD, Berry K, Moinpour C, et al: Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 97:1228-1234, 2002
18. Centers for Disease Control and Prevention: Faststats. http://www.cdc.gov/nchs/fastats
19. Centers for Disease Control and Prevention: 2013 ASP drug pricing files. http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrug AvgSalesPrice/2013ASPFiles.html
20. Centers for Disease Control and Prevention: 2013 Medicare physician fee schedule. http://www.cms.gov/ Medicare/Medicare-Fee-for-Service-Payment/Physician FeeSched/index.html?redirect=/physicianfeesched
21. Tumeh JW, Moore SG, Shapiro R, et al: Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 5:153-162, 2005
22. Lyman GH, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2189-2204, 2013
23. Schmoll HJ, Cunningham D, Sobrero A, et al: Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30:3588-3595, 2012
24. Goulart B, Ramsey S: A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14:836-845, 2011
25. Younossi ZM, Boparai N, McCormick M, et al: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 96:579-583, 2001
26. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25:1539-1544, 2007
27. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005
28. Shankaran V, Mummy D, Koepl L, et al: Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. Oncologist 19:892-899, 2014
29. Drummond M, Barbieri M, Cook J, et al: Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12:409-418, 2009
30. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
31. Vaiani M, Trippoli S, Messori A: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 344:305-306, 2001; author reply 306-307
32. Hillner BE, Schrag D, Sargent DJ, et al: Costeffectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104:1871-1884, 2005
33. Behl AS, Goddard KA, Flottemesch TJ, et al: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 104:1785-1795, 2012
34. Winkelmayer WC, Weinstein MC, Mittleman MA, et al: Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 22:417-430, 2002
35. Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 12:80-87, 2009
36. Husereau D, Drummond M, Petrou S, et al: Consolidated Health Economic Evaluation Reporting Standards (CHEERS): Explanation and elaboration-A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231-250, 2013
37. Medicare Payment Advisory Commission: Report to the Congress: Medicare Payment Policy. http:// www.medpac.gov/documents/reports/mar14- entirereport.pdf?sfvrsn=0
38. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
39. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
40. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
41. Lambrechts D, Lenz HJ, de Haas S, et al: Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219-1230, 2013